Allergan and Medicis are showing increased profits this quarter, and analysts are partially attributing the growth to third quarter Botox and Dysport sales.
According to CNN Money , revenues for Dysport manufacturer Medicis last quarter are 30 percent above last year’s figures. “We are encouraged by the positive physician and patient response to DYSPORT” said Medicis CEO Jonah Shacknai.
While other products may have played a role, Dysport sales were a major factor. Yet, the new drug still didn’t manage to hurt sales of Botox, the only competitor on the market right now.
Aided by a 3 percent increase in Botox sales, “Allergan’s third quarter profit rose 8.3 percent” reports the Wall Street Journal. New treatment applications are also in the works, which would likely drive sales further.
Although there’s been a positive response to Dysport in Little Rock , the brand awareness of Botox is still a major factor affecting sales, and that probably won’t change anytime soon.
Do you have questions or concerns about plastic or cosmetic surgery in Arkansas? 
Join us for a Fall Open House celebrating our new surgery center, October 27 from 4-8 pm. 
